The amount of interest and other costs that an entity incurs in connection with the borrowing of funds.

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Note Expiry date 2027-01-01
-Name IAS
-Number 1
-IssueDate 2025-01-01
-Paragraph 112
-Subparagraph c
-URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_112_c&doctype=Standard
-URIDate 2025-03-27

+ Details

Name:	ifrs-full_BorrowingCostsIncurred
Namespace Prefix:	ifrs-full_
Data Type:	xbrli:monetaryItemType
Balance Type:	na
Period Type:	duration

- Definition

The amount, at acquisition date, of contingent consideration arrangements recognised as consideration transferred in a business combination. [Refer: Total for all business combinations [member]]

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 3
-IssueDate 2025-01-01
-Paragraph B64
-Subparagraph g
-Clause i
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2025-en-r&anchor=para_B64_g_i&doctype=Appendix&subtype=B
-URIDate 2025-03-27

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Note Effective 2027-01-01
-Name IFRS
-Number 19
-IssueDate 2025-01-01
-Paragraph 35
-Subparagraph f
-Clause i
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_35_f_i&doctype=Standard
-URIDate 2025-03-27

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Note Effective 2027-01-01
-Name IFRS
-Number 19
-IssueDate 2025-01-01
-Paragraph 35
-Subparagraph f
-Clause i
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_35_f_i&doctype=Standard
-URIDate 2025-03-27

+ Details

Name:	ifrs-full_ContingentConsiderationRecognisedAsOfAcquisitionDate
Namespace Prefix:	ifrs-full_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.

+ References

No definition available.

+ Details

Name:	ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems
Namespace Prefix:	ifrs-full_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

The increase (decrease) in the number of ordinary shares issued. [Refer: Ordinary shares [member]]

+ References

+ Details

Name:	ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued
Namespace Prefix:	ifrs-full_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	duration

- Details

Name:	ifrs-full_TypesOfContractsAxis=aapg_HealthquestPharmaAcquisitionAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	ifrs-full_BorrowingsByNameAxis=aapg_DrYangMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Related Party Transactions (Details) ¥ in Thousands, $ in Thousands				12 Months Ended
	Jul. 29, 2025 CNY (¥)	Jul. 17, 2025 shares	Jun. 30, 2023 shares	Dec. 31, 2023 shares	Dec. 31, 2025 CNY (¥)	Dec. 31, 2025 USD ($)
Related Party Transactions [Line Items]
Ordinary shares (in Shares)			71,034	911,062
Healthquest Pharma Acquisition Agreement [Member]
Related Party Transactions [Line Items]
Contingent consideration amount					¥ 29,533	$ 4,223
Dr. Yang [Member]
Related Party Transactions [Line Items]
Ordinary shares (in Shares)		22,000,000
Borrowing cost \| ¥	¥ 3,933